IHS Chemical Week

Regions :: North America :: U.S.

Aurobindo receives FDA approval for generic Cymbalta

5:17 AM MST | December 13, 2013 | Natasha Alperowicz

Aurobindo Pharma (Hyderabad) said today that it has received final approval from the FDA to manufacture and market duloxetine hydrochloride delayed-release capsules 20, 30 and 60 mg. The product is the generic equivalent of Eli Lilly’s Cymbalta drug, used to treat major depressive disorders. The market size in the US for this product last year was estimated by IMS to be in the region of $5.4-5.5 billion.   Aurobindo is the third Indian company to announce FDA’s approval for the product. On Thursday Sun Pharmaceutical Industries (Mumbai) and Lupin...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa